# MonumenTAL-1 (NCT03399799)

> Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03399799
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Hematological Malignancies
- Interventions: Talquetamab
- Enrollment: 279
- Primary outcome: Part 1: Dose-limiting Toxicity (DLT)
- Primary outcome: Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 48
- YouTube: 36
- Podcasts: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=monumental-1-nct03399799

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03399799", "email": "<work email>"}; the inbox owner confirms by the emailed link.